NCT03337165View on ClinicalTrials.gov

Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

August 31, 2019

Conditions
Musculoskeletal DiseasesJoint DiseaseArthritisArthritis, RheumatoidRheumatic DiseasesConnective Tissue DiseasesAutoimmune DiseasesImmune System Diseases
Interventions
BIOLOGICAL

tolerogenic dendritic cells

dose-escalation

Trial Locations (1)

630099

Institute of Fundamental and Clinical Immunology, Novosibirsk

All Listed Sponsors
lead

Russian Academy of Medical Sciences

OTHER

NCT03337165 - Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter